Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a neurological disorder characterized by progressive weakness and impaired sensory function in the arms and legs.

Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

VIEW ALL VIDEOS

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

8:25 MIN

CIDP

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

DOWNLOAD PDF

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

15:31 MIN

CIDP

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

DOWNLOAD PDF

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

12:13 MIN

CIDP

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

DOWNLOAD PDF

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

13:53 MIN

CIDP
GBS
MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

DOWNLOAD PDF

NOW PLAYING

8:25

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Th...

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

NOW PLAYING

15:31

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Poly...

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

NOW PLAYING

12:13

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabiliza...

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

NOW PLAYING

13:53

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

Our Experts on CIDP

VIEW ALL EXPERTS

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

Jeffrey A. Allen, MD

University of Minnesota

Jeffrey A. Allen, MD

University of Minnesota

CIDP
MMN

Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

CIDP

Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

CIDP

Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.

What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?

What are the symptoms of CIDP?

How is CIDP treated?